Muhammed Jabir

Muhammed Jabir

Auto-generated profile, based on publicly available information

Muhammed Jabir

ICMR - Vector Control Research Centre, Puducherry, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2025 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
MJMuhammed Jabir
Muhammed Jabir
Manju RahiManju Rahi
Manju Rahi
India has set an ambitious target to achieve the elimination of lymphatic filariasis (LF) as a public health problem by 2027, 3 years ahead of the global target. Achieving this goal demands accelerated progress and evidence-based strategies. This review synthesises insights from the policies and interventions of 21 countries that achieved LF elimination in the past decade (2015–2024). Key lessons for India include integrated disease management, tailored drug distribution, capacity building, targeted outreach to migrant and never-treated populations and enhanced morbidity management strategies. It also highlights the role of robust social mobilisation, vector control strategies and strategic deployment of digital technologies. Tailoring these global practices to India’s diverse contexts can address the existing challenges and strengthen last-mile elimination efforts. Moreover, these insights provide a valuable blueprint for other endemic nations striving to achieve similar goals.

30 January 2026 in BMJ Open
Verified
Journal Article
Open access
ASAdinarayanan Srividya
Adinarayanan Srividya
RDRaja J Dinesh
Raja J Dinesh
MMMuhammed Jabir M M
Muhammed Jabir M M
MKManikandan Kishanthini
Manikandan Kishanthini
VDVishal Dogra
Vishal Dogra
Manju RahiManju Rahi
Manju Rahi
Introduction: India targets to eliminate lymphatic filariasis (LF) in alignment with the global goals. By 2024, 106 out of a total of 345 endemic districts have passed all three serial transmission assessment surveys (TAS) and are under post-mass drug administration (MDA) surveillance for a variable period. However, the current epidemiological situation of LF is not known in these districts. With increased mobility of population from the endemic districts currently under MDA to these post-MDA areas, resurgence of LF in these areas cannot be ruled out. Therefore, a study is planned to understand the current LF status in areas under post-MDA surveillance with the following objectives: (1) To assess the epidemiological situation of LF in terms of human and vector infection prevalence in selected evaluation units (EUs) under different durations of post-MDA phase and (2) to estimate the filarial infection (in terms of filarial antigen and microfilaria) among migrants (from endemic districts) in these EUs. Methods and analysis: This cross-sectional study will measure the filarial infection in (1) adult population aged ≥20 years (following the WHO 2025 protocol for monitoring and evaluation of MDA) among general population (n=3150 per EU), (2) migrant population (aged 2 years and above) in the post-MDA area originating from endemic areas (n=1000 per EU) and (3) vectors (n=7500 per EU) using molecular xenomonitoring (MX) to confirm sustenance of transmission interruption or identify any potential risk of resurgence in three EUs under post-MDA phase. In one MDA-naive EU that shares borders with endemic districts, filarial infection status will be assessed in (1) school children aged 9–14 years (as per WHO mini-TAS protocol, n=480), (2) migrants (aged 2 years and above) from endemic areas (n=1000) and (3) vectors (n=7500). EU-wide prevalence of microfilaria, circulating filarial antigen and vector infection rates with 95% CIs will be estimated. Multivariate logistic regression analysis will be carried out to find factors associated with LF positivity. In addition, knowledge, attitude and practice surveys will also be conducted among the adult migrants (n=1000 per EU). Thirty in-depth interviews will be conducted among the migrants, local community and health workers (in each EU) and the results will be suitably analysed and triangulated. The study results will enable the national programme to confirm sustenance of transmission interruption or assist in taking a decision to reinitiate MDA in these areas under post-MDA surveillance. It will also enable devising specific strategies to treat migrants. Ethics and dissemination: This study has been approved by the institutional ethics committee (IHEC 03-0824/N/F). A workshop will be held with all stakeholders to disseminate the study findings.

23 March 2025 in Acta Tropica
Verified
Journal Article
Closed access
MJMuhammed Jabir
Muhammed Jabir
SMSudipta Maiti
Sudipta Maiti
DJDinesh Raja Jeyapal
Dinesh Raja Jeyapal
ACAnoop C Choolayil
Anoop C Choolayil
DRDhanalakshmi Rajendran
Dhanalakshmi Rajendran
JPJency Priskilla
Jency Priskilla

9 February 2026 in BMJ Open
Verified
Journal Article
Open access
ARArya Rahul
Arya Rahul
KTKannan Thiruvengadam
Kannan Thiruvengadam
RSRohit Sharma
Rohit Sharma
MJMuhammed Jabir
Muhammed Jabir
AVAnju Viswan
Anju Viswan
Manju RahiManju Rahi
Manju Rahi
Introduction: Malaria remains a major public health challenge in India, with transmission dynamics varying widely across ecological, epidemiological, sociobehavioural and health system contexts. Achieving the national malaria elimination target by 2030 requires integrated, context-specific evidence to design effective interventions. This study aims to generate a comprehensive understanding of malaria transmission and factors surrounding it across diverse eco-epidemiological settings in India by assessing malaria burden, identifying determinants of transmission, evaluating health system performance and equity, characterising vector bionomics and insecticide resistance, and examining the influence of environmental drivers. Methods and analysis: This longitudinal, multicentric study will be conducted in collaboration with the national programme in 12 districts spanning 10 states in India, covering a population of around 25 000 individuals representing varied ecological contexts (urban, periurban, rural, forest-foothill and coastal) and malaria endemicity levels. In each district, two clusters (villages) with a population of 1000 individuals will be included. A baseline mass survey will estimate malaria prevalence using bivalent rapid diagnostic tests (RDTs) and blood smear microscopy, with low-density parasitaemia detected by PCR in a subset of RDT-negative samples. Participants will be followed for 1 year, with monthly screening of symptomatic individuals using RDT and microscopy, and testing a subset of asymptomatic individuals to detect subclinical infections. Sociobehavioural data will be collected through structured interviews and household observations, with purposive inclusion of vulnerable groups, pregnant women, migrants, elderly persons, individuals with disabilities and tribal populations to assess equity dimensions through mixed-methods approaches. Health system performance will be evaluated through key informant interviews with programme officials, health workers, patients, private practitioners and traditional healers. Entomological surveillance will document vector species composition, density, infection rates and assessment of susceptibility status and intensity of insecticide resistance to commonly used public health insecticides. Environmental variables, including temperature, rainfall and humidity, will be linked with entomological and epidemiological data to explore spatiotemporal relationships. Ethics and dissemination: The protocol was approved by the Institute Human Ethics Committee of ICMR-Vector Control Research Centre (IHEC 03-0125/N/F). All standard ethical practices will be adhered to. The findings will be shared with stakeholders and published in reputed open-access journals.

19 March 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
RDRaja J Dinesh
Raja J Dinesh
ASAdinarayanan Srividya
Adinarayanan Srividya
MJMuhammed Jabir
Muhammed Jabir
MKManikandan Kishanthini
Manikandan Kishanthini
VDVishal Dogra
Vishal Dogra
Manju RahiManju Rahi
Manju Rahi
Introduction With the global lymphatic filariasis (LF) elimination goal set to 2030, it is necessary to address challenges hindering the last-mile efforts. Never treated individuals are those who self-report that they have never taken the drugs for LF during any mass drug administration (MDA) rounds. Hence, it is necessary to identify these individuals and assess if they can be potential reservoirs of infection and understand the reasons for non-compliance. Methods and analysis This mixed method study, proposed for a period of 2 years, will assess the filarial infection status of never treated individuals from four LF-endemic districts in India. A multi-stage cluster sampling design will be followed to select the health subcentres from one highly endemic block in each of the selected districts. A random sample of 2535 never treated individuals from each block will be assessed for filarial infection by a cross-sectional blood survey. Qualitative surveys, including in-depth interviews and focus group discussions, will be conducted to elicit the reasons for their non-compliance. The prevalence of filarial infection will be summarised as frequencies and percentages. Univariate and multivariate logistic regression analysis will be performed to find the factors associated with filarial infection. Exploring the various reasons, such as sociocultural, behavioural and programmatic drivers of non-participation, will enable the programme to design tailored communication and community engagement strategies to bring them under the umbrella of MDA and thereby support the ongoing LF elimination efforts. Ethics and dissemination This study has been approved by the institutional ethics committee (IHEC 07-0824/N/F, dated 25 September 2024). After completion of the study, a workshop will be held with all stakeholders to disseminate the study findings.